Skip to main content
SpringerLink
Log in

Treatment of HIV Infection in Pregnant Women

Antiretroviral Management Options

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Increasing rates of HIV infection in women worldwide, especially among those of childbearing age, reinforce the importance of understanding the management of HIV in pregnancy. Over the past decade, significant advances have been made in the prevention of vertical HIV transmission, including the use of single and combination antiretroviral therapy, elective caesarean section as the preferred mode of delivery and the elimination of breast feeding.

Multiple clinical trials assessing antiretroviral therapy in pregnancy have been carried out worldwide. The first pivotal clinical trial, the AIDS Clinical Trials Group (ACTG) 076 study, was conducted in 1994 using a three-part zidovudine regimen. Despite the success of this regimen at decreasing rates of vertical transmission, it is not affordable in many developing countries. Consequently, many international clinical trials have concentrated on short-course antiretroviral regimens including zidovudine alone, zidovudine and lamivudine, and nevirapine alone.

In the developed world, the management of nonpregnant HIV-infected individuals has also undergone significant advances and has implications for the management of HIV in pregnancy. A number of countries have participated in the development of guidelines for the management of HIV in pregnancy, which recommend that HIV-infected pregnant women should be offered combination antiretroviral therapy based on viral load and CD4+ cell count cut-offs used for individuals who are not pregnant, preferably with the inclusion of zidovudine. However, to maximise the benefits to their offspring, therapy is recommended at lower viral load thresholds than for nonpregnant adults. For antiretroviral-naive women, therapy is deferred until the second trimester because of the potential and uncertain risk of teratogenesis and the low risk of transmission during this period. Research has also found that maternal factors including viral load, immune status, chorioamnionitis, prematurely ruptured membranes and, to a lesser extent, intravenous drug use and smoking are associated with increased vertical transmission. These represent potentially modifiable risk factors that should be addressed before and throughout pregnancy.

Despite the benefits of antiretroviral therapy to reduce HIV vertical transmission, its use can be complicated by known and unknown risks of toxicity to the mother, fetus or both as well as carrying the risk of developing drug-resistant virus. The latter can potentially compromise future treatment options for both the mother and child. Other important challenges include the use of antiretroviral drugs during pregnancy when the mother does not meet criteria for them for her own health, and balancing the relative risks and benefits of elective caesarean section at various degrees of viral load suppression. Clinicians managing HIV in pregnancy need to keep up to date with all the literature to provide optimal care, including counselling to allow mothers to balance the risks and benefits while deciding on treatment for both themselves and their children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. UNAIDS/WHO. AIDS epidemic: December 2002. Geneva: UNAIDS, 2002

  2. De Cock KM, Mbori-Ngacha D, Marum E. Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century. Lancet 2002; 360(9326): 67–72

    Article  PubMed  Google Scholar 

  3. Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002; 359(9323): 2097–104

    Article  PubMed  Google Scholar 

  4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331(18): 1173–80

    Article  PubMed  CAS  Google Scholar 

  5. Fiscus SA, Adimora AA, Funk ML, et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J 2002; 21: 664–8

    Article  PubMed  Google Scholar 

  6. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001; 15(6): 761–70

    Article  Google Scholar 

  7. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288(2): 222–35

    Article  PubMed  CAS  Google Scholar 

  8. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2003 Jun 16]

  9. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183(4): 539–45

    Article  PubMed  CAS  Google Scholar 

  10. Coll O, Fiore S, Floridia M, et al. Pregnancy and HIV infection: a European consensus on management. AIDS 2002 Jun 2; 16 Suppl. 2: S1–S18

    Article  PubMed  Google Scholar 

  11. Burdge DR, Money DM, Forbes JC, et al. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). CMAJ 2003; 168(13): 1671–4

    PubMed  Google Scholar 

  12. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997 Jun; 421: 1–9

    Article  PubMed  CAS  Google Scholar 

  13. Tscherning-Casper C, Papadogiannakis N, Anvret M, et al. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. J Virol 1999; 73(11): 9673–8

    PubMed  CAS  Google Scholar 

  14. Rogers AB, Hoover EA. Maternal-foetal feline immunodeficiency virus transmission: timing and tissue tropisms. J Infect Dis 1998; 178(4): 960–7

    Article  PubMed  CAS  Google Scholar 

  15. CDC. US Public Health Service Task Force: safety and toxicity of individual antiretroviral agents in pregnancy [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2003 May 23]

  16. Tuomala RE, Shapiro D, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of adverse outcome. N Engl J Med 2002; 346: 1863–70

    Article  PubMed  Google Scholar 

  17. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32(4): 380–7

    Article  Google Scholar 

  18. European Collaborative Study. Swiss mother and child HIV cohort study: combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14(18): 2913–20

    Article  Google Scholar 

  19. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184(9): 1120–6

    Article  PubMed  CAS  Google Scholar 

  20. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIV-1NET 012). AIDS 2001; 15(15): 1951–7

    Article  PubMed  CAS  Google Scholar 

  21. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002; 30(2): 200–15

    PubMed  CAS  Google Scholar 

  22. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353(9155): 773–80

    Article  PubMed  CAS  Google Scholar 

  23. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet 1999; 353(9155): 781–5

    Article  PubMed  CAS  Google Scholar 

  24. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group: Diminution de la Transmission Mere-Enfant. Lancet 1999; 353(9155): 786–92

    CAS  Google Scholar 

  25. Lallemant M, Jourdain G, Kim S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343(14): 982–91

    Article  PubMed  CAS  Google Scholar 

  26. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354(9181): 795–802

    Article  PubMed  CAS  Google Scholar 

  27. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359(9313): 1178–86

    Article  Google Scholar 

  28. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1: South African Intrapartum Nevirapine Trial (SAINT) Investigators. J Infect Dis 2003; 187(5): 725–35

    Article  PubMed  CAS  Google Scholar 

  29. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 1994; 8(3): 313–21

    Article  PubMed  CAS  Google Scholar 

  30. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335(22): 1621–9

    Article  PubMed  CAS  Google Scholar 

  31. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002; 16(4): 631–41

    Article  PubMed  CAS  Google Scholar 

  32. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 2002; 288(2): 189–98

    Article  PubMed  CAS  Google Scholar 

  33. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12(18): F241–7

    Article  PubMed  CAS  Google Scholar 

  34. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission: Women and Infants’ Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 2002; 29(5): 484–94

    CAS  Google Scholar 

  35. Duran A, Hackim A, Zlatkes R, et al. Impact of combined antiretroviral therapy on perinatal HIV transmission [abstract no. WePeB5941]. Proceedings of XlVth International AIDS Conference; 2002 Jul 7–12; Barcelona

  36. Melzi S, Chiesa E, Angeli E, et al. Use of different antiretroviral regimens during pregnancy in a cohort of 65 women in Italy [abstract no. MoPeD3682]. Proceedings of XIVth International AIDS Conference; 2002 Jul 7–12; Barcelona

  37. de Vincenzi I, Gaillard P, Farley T. Impact of highly active anti-retroviral treatment (HAART) during pregnancy and breastfeeding on mother-to-child HIV transmission (MTCT) and mother’s health in developing countries [abstract no. WePeB5953]. Proceedings of XIVth International AIDS Conference; 2002 Jul 7–12; Barcelona

  38. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341(6): 394–402

    Article  PubMed  CAS  Google Scholar 

  39. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997; 3(5): 549–52

    Article  PubMed  CAS  Google Scholar 

  40. Kovacs A, Wasserman SS, Burns D. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358(9293): 1593–601

    Article  PubMed  CAS  Google Scholar 

  41. Rich KC, Fowler MG, Mofenson LM, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants: Women and Infants Transmission Study Group. Pediatrics 2000; 105(1): e8

    Article  PubMed  CAS  Google Scholar 

  42. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13(11): 1377–85

    Article  Google Scholar 

  43. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and the mother-to-child transmission of human immunodeficiency virus type 1: the French Perinatal Cohort Studies. J Infect Dis 1997; 175(1): 172–5

    Article  PubMed  CAS  Google Scholar 

  44. Contopoulos-Ioannidis DG, Ioannidis JP. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(2): 126–35

    Article  PubMed  CAS  Google Scholar 

  45. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL:http://www.aidsinfo.nih.gov/ [Accessed 1998 Jan 30]

  46. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2000 Feb 25]

  47. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2000 Nov 3]

  48. CDC. US Public Health Service Task Force Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2001 Jan 24]

  49. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2002 Feb 4]

  50. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2002 Aug 30]

  51. Balani SK, Kauffman LR, deLuna FA, et al. Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab Dispos 1999; 27(1): 41–5

    PubMed  CAS  Google Scholar 

  52. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16(2): 299–300

    Article  PubMed  Google Scholar 

  53. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354(9184): 1084–9

    Article  PubMed  CAS  Google Scholar 

  54. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr Hum Retrovirol 2000; 25(3): 261–8

    Google Scholar 

  55. Marcus K, Truffa M, Boxwell D, et al. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA’s Adverse Event Reporting System (AERS) [abstract no. LB14]. In: Proceedings of 9th Conference of Retro viruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA). Alexandria (VA): Foundation for Retrovirolog and Human Health, 2002

    Google Scholar 

  56. Hirsch MS, Brun-Vezinet F, D’Aquila RT, et al., for the International AIDS Society-USA Panel. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283(18): 2417–26

    Article  PubMed  CAS  Google Scholar 

  57. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study Group. AIDS 2000; 14(3): 263–71

    Article  PubMed  CAS  Google Scholar 

  58. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999 179(3): 705–8

    Article  PubMed  CAS  Google Scholar 

  59. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177(3): 557–64

    Article  PubMed  CAS  Google Scholar 

  60. Giuliano M, Galluzzo T, Amici R, et al. Selection of resistance mutations in pregnant women receiving short-course antiretroviral regimens with ZDV and 3TC to prevent perinatal transmission (PETRA Study) [abstract no. 802-W]. In: Proceedings of 9th Conference of Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA). Alexandria (VA): Foundation for Retrovirolog and Human Health, 2002

    Google Scholar 

  61. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternalinfant transmission of HIV-1. JAMA 2001; 285(16): 2083–93

    Article  PubMed  CAS  Google Scholar 

  62. Nair P, Alger L, Hines S, et al. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993; 6(3): 298–302

    PubMed  CAS  Google Scholar 

  63. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15(3): 357–68

    Article  Google Scholar 

  64. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine: Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341(6): 385–93

    Article  PubMed  CAS  Google Scholar 

  65. Shey WI, Brocklehurst P, Sterne JA, et al. Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002; (3): CD003648

  66. Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine: Pediatric AIDS Clinical Trials Group 185 Team. AIDS 2000; 14(10): 1389–99

    Article  PubMed  CAS  Google Scholar 

  67. Shey WI, Brocklehurst P, Sterne JA, et al. Vaginal disinfection during labour for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002; (3): CD003651

  68. The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353(9158): 1035–9

    Article  Google Scholar 

  69. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340(13): 977–87

    Article  Google Scholar 

  70. Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum morbidity among HIV-infected women: the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2001; 26(3): 236–45

    Article  PubMed  CAS  Google Scholar 

  71. Patel J, Melville S, Heath C, et al. Role of combination antiretroviral therapy and mode of delivery in perinatal HIV transmission (PHT), pediatric spectrum of disease project (PSD), United States, 1995–2000 [abstract no. 798-W]. In: Proceedings of 9th Conference of Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA). Alexandria (VA): Foundation for Retrovirolog and Human Health, 2002

    Google Scholar 

  72. Ghosh MK, Kuhn L, West J, et al. Quantitation of human immunodeficiency virus type 1 in breast milk. J Clin Microbiol 2003; 41(6): 2465–70

    Article  PubMed  CAS  Google Scholar 

  73. Nduati R, Richardson BA, John G, et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357(9269): 1651–5

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Mona Loutfy is supported by a postdoctoral fellowship award from the Canadian Institutes of Health Research and Sharon Walmsley by a career scientist award from the Ontario HIV Treatment Network. The authors would like to thank Roberta Halpenny for assisting with constructing the tables. The authors have provided no information on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University, Montreal, Quebec, Canada

    Mona R. Loutfy

  2. Department of Medicine, Immunodeficiency Clinic, University Health Network, University of Toronto, Toronto, Ontario, Canada

    Sharon L. Walmsley

Authors
  1. Mona R. Loutfy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharon L. Walmsley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharon L. Walmsley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loutfy, M.R., Walmsley, S.L. Treatment of HIV Infection in Pregnant Women. Drugs 64, 471–488 (2004). https://doi.org/10.2165/00003495-200464050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464050-00002

Keywords

Search

Navigation